# IMI 3rd Call
Presentation of *indicative* Call topic titles

Titta Rosvall-Puplett
Director, EFPIA Research Directors Group

Indicative Call topics

- The aim of presenting *"Indicative Call topic titles"* is to give you a better idea of possible topics you can expect to be addressed in the 3rd IMI Call

- The indicative topics are based on the 2010 Scientific Priorities, published in March

- Note that not all Scientific Priorities will be covered in the 3rd Call

IMI Scientific Priorities 2010   16 March 2010

IMI Scientific Priorities 2010

Disclaimer:
Please note that the Scientific Priorities set forth hereunder should not, in any case, be regarded as the topics for the 3rd Call of the IMI JU.

Summary of Scientific Priorities

| Priority	Title	Pillar	Scientific Area
A	Assessment of drug induced toxicity in relevant organs - surrogates for early drug failure	Safety	General Safety
B	Immunological Safety of Biopharmaceuticals	Safety	Immunology
C	Assessment inflammatory disease	Efficacy	Inflammatory Diseases
D	Improve the scientific and pre-clinical infrastructure for Tuberculosis medicine	Efficacy	Infectious Diseases
E	Enhancing translation in neurological disease	Efficacy	CNS
F	Development of personalized medicine approaches in diabetes	Efficacy	Metabolic Diseases
G	Fostering a broader understanding of pharmaceutical R&D in the broader public	Education & Training	

IMI's pillar structure

- **The 3rd IMI Call may address:**
  - Safety
 - Efficacy
  - Education & Training

Possible Safety topic titles

- Improved early prediction of Drug Induced Liver Injury in man (DILI)

- Cardiovascular Safety

- Immunogenicity: Assessing the Clinical Relevance and Risk Minimization of Antibodies to Biopharmaceuticals

- Immunosafety of vaccines – New biomarkers associated with adverse events (early inflammation and autoimmune disease)

Possible Efficacy topic titles

- Improve the scientific and preclinical models and tools for Tuberculosis medicines research

- Functional MRI applications in CNS drug development

- Translational endpoints for autism

- Personalized Medicine in Diabetes treatment

Scanning Electron Micrograph of Mycobacterium tuberculosis

Possible Education & Training topic title

- Training programs for the informed patient

Overview of **possible** topic titles in the 3rd Call

- Improved early prediction of Drug Induced Liver Injury in man

- Cardiovascular safety

- Immunogenicity: Assessing the Clinical Relevance and Risk Minimization of Antibodies to Biopharmaceuticals

- Immunosafety of Vaccines:
  New Biomarkers associated with adverse events (early inflammation and autoimmune disease)

- Improve the scientific and preclinical models and tools for Tuberculosis medicines research

- Functional MRI applications in CNS drug development

- Translational endpoints for autism

- Personalized Medicine in Diabetes treatment

- Training programs for the informed patient

Thank you for your attention

Let us continue to create
innovative partnerships
in the 3rd IMI Call

Good luck with your application